Innate immunity and nonalcoholic fatty liver disease

Area of Science:

• Hepatology
• Immunology
• Metabolic Diseases

Background:

• Nonalcoholic fatty liver disease (NAFLD), now metabolic (dysfunction)-associated fatty liver disease (MAFLD), affects up to 33% globally.
• MAFLD is linked to metabolic syndrome and shows a significant immune-inflammatory component.
• Progression to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma involves innate immune cell activation.

Purpose of the Study:

• To review current understanding of innate immune system involvement in MAFLD/NAFLD/NASH.
• To explore stress signals that disrupt immune tolerance and trigger adverse immune responses.
• To highlight the need for further research into specific innate immune cell subsets for therapeutic development.

Main Methods:

• Review of current literature on innate immunity in MAFLD/NAFLD/NASH.
• Discussion of immune-inflammatory pathways and stress signals.
• Synthesis of knowledge on immune cell roles in disease pathogenesis.

Main Results:

• Innate immune cells are heavily involved in MAFLD/NAFLD/NASH onset and progression.
• Aberrant immune responses are triggered by stress signals affecting immune tolerance.
• Current understanding of specific immune cell roles and inflammatory signals remains fragmented.

Conclusions:

• A comprehensive understanding of innate immune mechanisms in MAFLD/NAFLD/NASH is crucial.
• Identifying specific immune cell subsets and inflammatory drivers can lead to early interventions.
• Targeting innate immunity offers potential for innovative therapeutic strategies against MAFLD/NAFLD/NASH.